-The Indian Express A day after the deadline for implementation of the Right To Education (RTE) Act expired, representatives of the Delhi State Public Schools Association (DSPSA) met Chief Minister Sheila Dikshit and Education Minister Kiran Walia, seeking a reprieve. Speaking to Newsline, Walia said, "We have already brought down the minimum area requirement to 200 square meters. Beyond this, there are concerns of fire safety and other issues." She said the delegation...

-Reuters India's top court imposed a fine of Rs 100 crore ($18.40 million) on Sterlite Industries for polluting environment through its copper smelting plant in Tamil Nadu. The case is unrelated to a separate order that has shut the Tuticorin plant, India's largest, since last week following complaints of a gas leak. Despite the fine, the Supreme Court overruled an earlier order from the Madras High Court to shut down the plant over...

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...